Down 20% in a year, is the Cochlear share price a bargain buy?

Investors need to hear this: Some brokers think Cochlear is an opportunity.

| More on:
a woman leans forward with her hand behind her ear, as if trying to hear information.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Cochlear is a growing, global business that designs and makes hearing implants
  • Its revenue from services is rising quickly – HY22 services revenue went up 19%
  • Morgans thinks Cochlear is a buy with upside of more than 20%

The Cochlear Limited (ASX: COH) share price has fallen around 22% over the last year. While that’s not one of the biggest drops on the ASX in recent times, some experts think that the share has upside.

Cochlear is one of the ASX’s largest healthcare businesses. But is it a big opportunity? Some experts have had their say on the hearing device company.

But, first, let’s see how the business has been growing in recent times.

Latest profit update from Cochlear

The cochlear implant business reported in its FY22 half-year result that its 12% growth of sales revenue (in constant currency) to $815 million was driven by strong demand for sound processor upgrades and new acoustic implant products.

In HY22, cochlear implant units increased by 7% to 18,598. While services revenue increased 19% to $256.5 million and acoustics revenue jumped 38% to $100.9 million, cochlear implant revenue only went up 1% to $457.9 million.

The company’s underlying net profit after tax (NPAT) rose 26% to $159 million thanks to the combination of sales growth and an improved gross profit margin. It also experienced lower-than-expected operating expenses.

The business paid an interim dividend of $1.55 per share, representing a 35% increase.

The company said that its FY22 underlying net profit guidance is between $265 million to $285 million, equating to an increase of between 13% to 22% year on year.


A couple of months ago, Cochlear announced it was buying Oticon Medical, Demant’s hearing implant business, for approximately AU$170 million.

As part of the transaction, Cochlear has committed to providing ongoing support for Oticon Medical’s base of over 75,000 hearing implant recipients.

The attraction of the deal was that it would provide greater scale and enable increased investment in research and development, as well as market growth activities.

Oticon Medical is expected to add between A$75 million to A$80 million to annual revenue, though it’s currently loss-making.

Cochlear noted that while it’s a market leader in implantable hearing, it’s a small player in the hearing loss segment where hearing aids remain the primary treatment option.

Is the Cochlear share price an opportunity?

The broker Morgans certainly thinks so with a price target of $244.50. That implies a possible rise of more than 20%. Morgans likes the acquisition of Demant Oticon as it increases market share.

Based on Morgans’ estimates, the Cochlear share price is valued at 49 times FY22’s estimated earnings and 44 times FY23’s estimated earnings. Morgans also thinks that surgery delays caused by COVID-19 will help the outlook.

However, the broker Morgan Stanley only rates the business as ‘equal-weight’, which is like a ‘hold’ rating. It thinks margins could be challenged, though it notes the revenue growth of services and upgrades can help.

Morgan Stanley’s price target on the business is $208, which suggests a high single-digit rise in the share price.

Morgan Stanley thinks the Cochlear share price is valued at 45 times FY22’s estimated earnings and 40 times FY23’s estimated earnings.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

Medibank share price dips despite dividend boost

The healthcare insurer will pay its biggest final dividend since 2019.

Read more »

Three medical staffers sit at a table and chat happily wearing hospital scrubs
Earnings Results

Pro Medicus share price fails to fly on 44% profit leap

Here's how Pro Medicus dialled up the profits in FY22.

Read more »

A CSL scientist looking through a telescope in a lab
Earnings Results

Telix share price slides despite 726% revenue boost

Investors may be thinking the pharmaceutical company's valuation has peaked after the stock price doubled over the past three months.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Broker Notes

Broker gives its verdict on the CSL share price post-FY22 results

Here's what this broker is saying about the CSL share price...

Read more »

An older woman tries to listen by cupping her ear.
Healthcare Shares

Guess which ASX biotech share is soaring 32% on a ‘landmark’ FDA ruling

What a day it has become for this small-cap healthcare company.

Read more »

Two happy scientists analysing test results.
Dividend Investing

Everything you need to know about the latest CSL dividend

Own CSL shares? Here's the details regarding its latest dividend.

Read more »

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
Healthcare Shares

CSL share price drops despite expectations of growth in FY23

Investors are punishing CSL. What's going on?

Read more »

ventilator mask
Healthcare Shares

Why ‘the outlook is very bullish’ for the Resmed share price: Tribeca

ResMed has been rated as a buy by Tribeca.

Read more »